NASDAQ · LBRX
Healthcare · Biotechnology
$34.62
Down-$0.36 (-1.04%)
Updated Oct 6, 2026, 10:23 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LBRX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
LBRX closed at $34.62 after 20 trading sessions, down 29.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $36.41 | $36.88 | $34.47 | $34.62 | 494.49K |
| Oct 2, 2026 | $37.72 | $38.815 | $36.75 | $36.99 | 388.89K |
| Oct 1, 2026 | $38.10 | $38.59 | $37.125 | $37.28 | 278.89K |
| Sep 30, 2026 | $37.61 | $39.23 | $37.34 | $38.38 | 437.22K |
| Sep 29, 2026 | $37.89 | $38.13 | $36.98 | $37.28 | 713.38K |
| Sep 28, 2026 | $37.24 | $38.17 | $36.57 | $37.89 | 534.59K |
| Sep 25, 2026 | $37.85 | $38.57 | $36.99 | $37.33 | 398.94K |
| Sep 24, 2026 | $39.13 | $39.39 | $37.56 | $37.80 | 413.5K |
| Sep 23, 2026 | $42.80 | $42.80 | $38.835 | $39.19 | 481.68K |
| Sep 22, 2026 | $43.40 | $43.40 | $41.21 | $42.69 | 244.4K |
| Sep 21, 2026 | $42.55 | $43.22 | $41.535 | $42.99 | 310.16K |
| Sep 18, 2026 | $42.22 | $42.54 | $41.385 | $42.47 | 531.64K |
| Sep 17, 2026 | $43.33 | $43.50 | $41.78 | $42.14 | 314.5K |
| Sep 16, 2026 | $43.37 | $43.94 | $42.17 | $42.57 | 231.92K |
| Sep 15, 2026 | $44.84 | $44.84 | $42.50 | $43.04 | 320.55K |
| Sep 14, 2026 | $44.95 | $45.72 | $44.55 | $44.84 | 242.78K |
| Sep 11, 2026 | $46.80 | $47.68 | $44.40 | $44.63 | 208.38K |
| Sep 10, 2026 | $47.20 | $47.20 | $45.50 | $46.25 | 174.79K |
| Sep 9, 2026 | $49.07 | $49.81 | $47.46 | $47.67 | 190.14K |
| Sep 8, 2026 | $48.53 | $49.62 | $47.15 | $49.39 | 301K |
The latest Smart Investors Daily articles mentioning LBRX.
Company
Market Activity
Research & News
LBRX research
Company profile and research snapshot.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Roth Capital | Neutral | — |
| Oct 2, 2026 | Needham | Buy | — |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2026 | BMO Capital | Outperform | — |
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 18, 2026
LB Pharmaceuticals is a high-risk, high-reward play with sufficient cash showing early signals of benefit in the NOVA-1 trial. Read why LBRX stock is a buy.
Yahoo · Sep 15, 2026
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer. Dr. Kozauer is a leader in neuropsychiatric drug development with more than two decades of development expertise spanning early-stag
Yahoo · Sep 9, 2026
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
Yahoo · Sep 4, 2026
LB Pharmaceuticals (LBRX) has drawn fresh investor attention after appointing Joseph M. Miller as Chief Financial Officer. The announcement coincides with preparations for NOVA-2 trial readouts and a potential LB-102 launch in schizophrenia. Despite a pullback over the last day with a 1-day share price return of down 3.96% to US$47.52, LB Pharmaceuticals has delivered a 66.56% 90-day share price return and a 132.49% year-to-date share price return, which suggests that momentum has been...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LBRX.
